RecruitingPhase 2NCT04204850

Cabozantinib to Treat Recurrent Liver Cancer Post Transplant

A Phase II Trial of Cabozantinib in the Treatment of Recurrent Hepatocellular Carcinoma Post Liver Transplant

Sponsor

University Health Network, Toronto

Enrollment

20 participants

Start Date

Aug 7, 2020

Study Type

INTERVENTIONAL

Conditions

Hepatocellular Carcinoma Liver Transplant Recurrent Cancer

Summary

This is a phase 2 study that will assess the investigational drug, cabozantinib, in patients with liver cancer (specifically hepatocellular carcinoma) and who had received a liver transplant as a part of curative care, but the cancer has come back (recurred). The purpose of this study is to see how useful cabozantinib is in controlling the disease of these patients. Cabozantinib blocks the function of various proteins found on the surface of the body's cells (called receptor tyrosine kinases) that are important in the development of cancer tumors. All participants will receive cabozantinib until they are no longer receiving benefit from the study drug or they experience an intolerable side effect.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing cabozantinib, a targeted therapy drug, for patients whose liver cancer (hepatocellular carcinoma) has come back after a liver transplant, to see if it can slow or stop the cancer's growth. **You may be eligible if...** - You have liver cancer (hepatocellular carcinoma) confirmed by biopsy or imaging that has recurred after a liver transplant - You had the liver transplant specifically to treat the liver cancer - Surgery or local treatment for the recurrence is not feasible - You have measurable disease on scans - You are 18 or older with a good performance status (ECOG 0–1) - You have adequate heart, kidney, and liver function - You have had no prior treatment with cabozantinib **You may NOT be eligible if...** - You have never had a liver transplant - You have already been treated with cabozantinib - You have active uncontrolled infections - Your organ function is too impaired for treatment Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.